AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study
August 14 2019 - 03:00AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Wednesday that its cancer drug
Lynparza has again shown positive results as a treatment for
advanced ovarian cancer in a phase 3 study.
Lynparza was being administered as a first-line maintenance
therapy in women regardless of BRCA gene mutation status.
The drug had previously met its primary endpoint as a treatment
for ovarian cancer in the Solo-1 trial.
According the FTSE 100-listed company, Lynparza combined with
olaparib--a standard medication for the disease--was able to
prolong the amount of time patients being administered the
treatment lived without disease progression or death when compared
to those just taking olaparib alone.
Lynparza, which is being developed jointly with Merck & Co.
Inc. (MRK), recently yielded positive results in another study as a
treatment for prostate cancer. It is the only drug in its
class--known as PARP inhibitors--that has shown to be effective in
phase 3 trials across ovarian, breast, pancreatic and prostate
cancer.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
August 14, 2019 02:45 ET (06:45 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024